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Abstract 23 
Background 24 
Fabry disease (FD), an X-linked lysosomal storage disorder, results from the deficient 25 
activity of α-galactosidase A (α-Gal A) and the accumulation of its substrates, 26 
globotriaosylceramide (Gb3) and its deacylated derivative, globotriaosyl-sphingosine 27 
(Lyso-Gb3). Here, we compared the levels of Lyso-Gb3 in dried blood spots (DBS) 28 
and sera in affected males and heterozygotes with the “Classic” and “Later-Onset” 29 
phenotypes. 30 
Methods 31 
The Lyso-Gb3 concentrations in DBS and sera from 56 FD patients were determined 32 
by highly sensitive electrospray ionization liquid chromatography tandem mass 33 
spectrometry. 34 
Results 35 
The serum Lyso-Gb3 levels in 18 and 5 affected males with the Classic and Later-36 
Onset phenotypes, were 61 ± 38 and 14 ± 12 ng/mL, respectively. Lyso-Gb3 levels in 37 
30 females from Classic families and three females from Later-Onset families were 38 
10 ± 5.4 and 2.4 ±1.0 ng/mL, respectively. The linear regression model with serum 39 
Lyso-Gb3 as the dependent variable and DBS Lyso-Gb3 an independent variable 40 
was described by the function y = - 1.83+1.68*x and showed a high coefficient of 41 
determination, R2= 0.976. The overall correlation between the Lyso-Gb3 levels in 42 
DBS and sera was high (R=0.99; p<0.001). 43 
Conclusion 44 
DBS provides a convenient, sensitive, and reproducible source to measure Lyso-Gb3 45 
levels for diagnosis, initial phenotypic assignment, and therapeutic monitoring in 46 
patients with Fabry Disease.  47 
  48 
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1. Introduction 50 
Fabry disease (FD), an X-linked inborn error of glycosphingolipid catabolism, results 51 
from pathogenic mutations in the α-galactosidase A gene (GLA) which markedly 52 
reduce or abolish lysosomal α-galactosidase A (α-Gal A) activity [1]. The enzymatic 53 
deficiency leads to the systemic lysosomal accumulation of globotriaosylceramide 54 
(Gb3), and other glycoconjugates with α-galactosyl terminal moieties [1], including 55 
the deacylated derivative of Gb3, globotriaosyl-sphingosine (Lyso-Gb3) [2]. The 56 
lysosomal accumulation of Gb3 and Lyso-Gb3 occurs preferentially in 57 
endothelial and epithelial cells as well as podocytes which is reflected in the 58 
clinical phenotype of Fabry disease. The diagnosis of FD is reliably made by the 59 
markedly deficient α-Gal A activity in affected males. In contrast, the α-Gal A activity 60 
in heterozygous females is variable, ranging from deficient to normal due to random 61 
X-chromosomal inactivation [3]. Therefore, suspected heterozygotes can be 62 
accurately diagnosed by GLA sequencing to demonstrate the familyial mutation [1].  63 
There are two major phenotypic subtypes of Fabry disease: the Type 1 “Classic” and 64 
the Type 2 “Later-Onset” phenotypes. Type 1 “Classically” affected males have little, 65 
if any, α-Gal A activity, marked vascular endothelial Gb3 accumulation, and the onset 66 
of disease manifestations in childhood or adolescence, including acroparesthesias, 67 
hypohidrosis, angiokeratoma, gastrointestinal pain and cramping, and corneal and 68 
lenticular opacities. With advancing age, the progressive glycosphingolipid 69 
deposition, particularly in vascular endothelial cells, cardiomyocytes, renal podocytes, 70 
and lysosomes, leads to hypertrophic cardiomyopathy, renal failure, cerebrovascular 71 
disease, and early demise, typically in the fourth or fifth decades of life [e.g.[4]. In 72 
contrast, males with the Type 2 Later-Onset phenotype have residual α-Gal A 73 
activity, lack the vascular endothelial Gb3 accumulations, and do not have the early 74 
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clinical manifestations of the classic males. These patients typically present in their 75 
fourth to sixth decades with cardiac, renal, and cerebrovascular disease, similar to 76 
Type 1 Classic males [5, 6]. Most patients with the Later-Onset phenotype were 77 
identified by screening hemodialysis, cardiac, and stroke clinics [e.g.[4, 7, 8] or more 78 
recently by newborn screening [9, 10]. The standard treatment for Fabry disease is 79 
enzyme replacement therapy (ERT) with the recombinant enzyme [11-14]. Phase 3 80 
Clinical trials and recent studies have emphasized the importance of early 81 
intervention in Classic males [11-14] and dose [15, 16].  82 
 83 
Recently, the concentration of serum or plasma Lyso-Gb3, has become an easily 84 
measured biomarker for disease activity [2] and as a therapeutic monitoring of ERT 85 
[e.g.[17, 18]. Also, Lyso-Gb3 values can be useful in evaluating heterozygotes for 86 
treatment [18, 19]. Since biomarkers ideally should be easy to collect, transport, and 87 
analyze, previously, we and others studies [20, 21] evaluated the use of dried blood 88 
spots (DBS) to measure Lyso-Gb3. Here, we report the first studies to determine the 89 
correlation between DBS and sera Lyso-Gb3 levels in affected males and 90 
symptomatic heterozygotes with both phenotypes. 91 
 92 
2. Methods 93 
2.1. Patients and control group: 94 
This study was conducted in accordance with the principles of the Helsinki 95 
Declaration. All patients signed a written informed consent. The study was 96 
approved by the Zurich Ethics Committee. All authors have read and approved 97 
the manuscript.  98 
 99 
  100 
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2.2 Lyso-Gb3 Determination and GLA Mutation Detection:  101 
The Lyso-Gb3 concentrations in DBS and sera obtained from the same blood sample 102 
were determined in FD patients who presented for an annual examination at the 103 
University Hospital Zurich, Switzerland. In previous studies, Lyso-Gb3 showed 104 
very similar results in plasma [2, 17] and serum [22, 23].  105 
The serum samples were immediately frozen at −80°C after centrifugation for 106 
subsequent batch analysis. The DBS cards and paired sera samples were sent by 107 
post to Vienna for Lyso-Gb3 analyses. The DBS cards for routine and stability 108 
analyses were sent from Zurich to Vienna in paper envelopes by post at 109 
ambient temperature (which can take up to 7 days) and then the DBS cards 110 
were stored at the room temperature prior to analysis. The frozen serum 111 
samples were sent on dry ice by an express courier to arrive at the laboratory 112 
within 24 hours. 113 
 114 
Lyso-Gb3 concentrations in DBS and sera were measured by highly-sensitive 115 
electrospray ionization liquid chromatography tandem mass spectrometry (ESI LC-116 
MS/MS) using a modified method based on Gold et al. [24] and recently described 117 
by Nowak et al. [19]. One DBS punch of 3.1 mm diameter was used for analysis 118 
in a microtiter plate. After extraction, the plate was sealed with adhesive 119 
aluminum-foil and shaken for 30 min on an Orbital shaker at 500 rpm. In brief, 120 
for chromatographic separation, a C18 UHPLC column and aqueous mobile 121 
phase consisting of H20 with 0.1% formic acid and an organic phase with 15% 122 
acetonitrile in methanol also containing 0.1% formic acid were used. For mass 123 
spectrometric analysis, 5 µl of the extracted DBS was injected. The total 124 
running time per sample was 4.2 minutes. To ensure maximum recovery, the 125 
plate was subsequently placed in an ultrasonic bath for 40 min. These settings 126 
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were optimized and, finally, no Lyso-Gb3 could be determined using the same 127 
DBS punch in a second extraction and same sample work-up procedure as 128 
describe above. A 7-point serum calibrator and an internal standard for Lyso-Gb3 129 
quantification (covering the analytic range from 0 to 120 ng/mL; lower limit of 130 
quantification: 0.2 ng/mL), and three calibrator levels (3, 30 and 100 ng/mL) for 131 
quality control were used (ARCHIMED Life Science GmbH, Vienna, Austria; 132 
www.archimedlife.com). The lower limit of quantification was determined 133 
according to EP guideline 17A2 using Lyso-Gb3 calibrators 0, 0.5 and 1.0 134 
ng/mL. The laboratory members were blinded to patient’s ID numbers, sex, and all 135 
clinical and biochemical information and were not involved in the collection of 136 
samples, interpretation of data, or the decision to submit this article for publication. 137 
Additional experimental details on mass spectrometric conditions and sample work-138 
up are available on request. 139 
The GLA mutations were identified by GLA gene sequencing as previously described 140 
by standard methods [9, 25]. The mutations of each patient are listed in 141 
Supplementary Table A1. 142 
 143 
2.3 Phenotyping: 144 
FD males and heterozygotes were classified as having the Type 1 Classic or Type 2 145 
Later-Onset phenotype based on the specific GLA mutation. In affected males, 146 
nonsense, frameshift, consensus splice site and certain missense mutations 147 
predict the early onset Type 1 phenotype and encode <1% of normal mean α-148 
Gal A activity. In contrast, certain missense mutations and alternative splicing 149 
mutations predict the Type 2 Later-Onset phenotype and encode >1% of 150 
normal mean α-Gal A activity. For each mutation, the phenotype was also 151 
based on age and onset and clinical manifestations. 152 
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For novel missense mutations, the phenotype was based on clinical signs and 153 
symptoms in affected males and by in vitro expression assays [9, 26].  154 
2.4. Statistical analysis 155 
We used descriptive statistics for the clinical characteristics and laboratory 156 
parameters. Categorical variables are expressed as proportions (percentage) and 157 
continuous variables as mean and standard deviation (SD). Comparison of groups 158 
was made using the Student t-test [27] and the Chi-squared test [28] as appropriate.  159 
A regression analysis was used to fit the linear model, R-squared was calculated to 160 
assess its goodness-of-fit [29]. A bivariate correlation [30] between DBS and serum 161 
values of Lyso-Gb3 was calculated.  162 
The Lyso-Gb3 stability in DBS cards was assessed after 1-month storage of the 163 
cards and was calculated as the percentage of Lyso-Gb3 after 1-month storage 164 
compared to the baseline Lyso-Gb3 level. The coefficient of variation (CV) was 165 
calculated as the ratio of the standard deviation to the mean. 166 
 167 
3. Results  168 
The Lyso-Gb3 determination was assessed for the reproducibility: in three affected 169 
male and two heterozygotes Type 1 Classic patients as well as in one healthy 170 
control. Ten DBS cards were prepared with the same blood sample from each 171 
patient. The results are presented in Table 1 to determine the stability of those 172 
samples. In general, the results of the DBS levels were highly reproducible for FD 173 
patients, the reproducibility increased with increasing Lyso-Gb3 levels.  174 
The Lyso-Gb3 determination was assessed for stability: in the three affected males, 175 
Lyso-Gb3 levels were remeasured from the same DBS samples one month later. The 176 
results of the DBS levels remained well reproducible The recovery for the Lyso-Gb3 177 
measurements was 91%; 91% and 105% respectively (Table 1). 178 
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Table 1. Reproducibility (CV) and stability (recovery) of DBS Lyso-Gb3 measurements *.  179 
Mutation Mean ± SD of Lyso-Gb3 levels 
in 10 DBS, ng/mL, at baseline 
CV at baseline, % Mean ± SD of Lyso-Gb3 levels 
in 10 DBS, ng/mL, at one month 
 
CV after one month, % Stability 
Recovery after 
one month, % 
Deletion Exon 2 
 
94 ± 4.3 4 99 ± 8.7 9 105 
c.581C>T 
 
44 ± 2.2 5 40 ± 2.9 7 91 
c.370-2A>G 
 
41 ± 2.0 5 37 ± 2.9 8 91 
c.1033T>C (mother) 
 
5.4 ± 1.4 12    
c.1033T>C (daughter) 
 
2.8 ± 1.7  12    
No Fabry disease 
 
1.8 ± 2.8 17    
 180 
*  In three males and two heterozygotes with the Type 1 Classic phenotype and one healthy control, 10 DBS were prepared for the 181 
same blood sample for each individual.   182 
Stability Recovery after one month was measured for the three Classic males. 183 
 184 
Abbreviations: CV, coefficient of variation; DBS, dried blood spots; SD, standard deviation. 185 
 186 
 187 
 188 
 189 
 190 
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Lyso-Gb3 levels were determined in DBS and sera prepared from the same 191 
blood sample of eight healthy controls.  Five normal males (aged 30 to 76 years) 192 
had DBS Lyso-Gb3 levels of 1.02 ± 0.08 (range: 0.9 to 1.1) ng/mL and sera Lyso-193 
Gb3 levels of 0.60 ± 0.08 (range: 0.46 to 0.65) ng/mL. Three normal females (aged 194 
42 to 65 years) had DBS Lyso-Gb3 levels of 0.75 ± 0.21 (range: 0.6 to 0.9) ng/mL 195 
and sera Lyso-Gb3 levels of 0.47 ± 0.12 (range: 0.33 to 0.55) ng/mL.  196 
Serum Lyso-Gb3 measurements in a healthy control group of 16 males (aged 197 
30 to 76 years) and 14 females (aged 17 to 65 years) ranged between 0.23 and 198 
0.65 ng/mL for males and 0.29 and 0.55 ng/mL for females. Overall mean for the 199 
30 healthy controls was 0.45 ng/mL (range 0.23 to 0.65 ng/mL). 200 
The Lyso-Gb3 levels in the DBS and sera from 23 males (mean age 46 years) and 201 
33 heterozygotes (mean age 47 years) were determined in DBS and sera. The 202 
clinical and biochemical characteristics of the patients are summarized in Table 2 203 
and shown in detail in (Table 3) Supplementary Table A1. The mean DBS Lyso-204 
Gb3 from the 18 Type 1 Classic males (aged 27 to 69 years) was 38 (range: 12 to 205 
89) ng/mL (hematocrit 0.42 ± 0.04 L/L) and 61 (range: 17 to 148) ng/mL in sera. 206 
Among the 30 heterozygotes (aged 20 to 70 years) from families with the Type 1 207 
Classic phenotype, the mean DBS Lyso-Gb3 concentration was 7.2 (range: 1.3 to 208 
17) ng/mL (hematocrit 0.41 ± 0.02 L/L) and 10 (range: 0.37 to 27) ng/mL in sera. In 209 
contrast, five affected males (aged 39 to 67 years) with the Later-Onset phenotype 210 
had mean median DBS Lyso-Gb3 concentrations of 5.4 8.4 (range: 3.1 to 23) ng/mL 211 
(hematocrit 0.44 ± 0.04 L/L) and 10 14 (range: 5.3 to 34) ng/mL in sera. In the three 212 
heterozygotes (aged 35 to 75 years) with the Later-Onset phenotype, the mean 213 
median DBS Lyso-Gb3 level was 1.3 1.7 (range: 1.1 to 2.6) ng/mL (hematocrit 0.43 ± 214 
0.01 L/L) and 2.1 2.4 (range: 1.6 to 3.6) ng/mL in sera. The DBS and serum Lyso-215 
Gb3 levels for each FD patient are shown in Supplementary Table A1.216 
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Table 2. Clinical and biochemical characteristics. 217 
 Affected Males, N=23 Heterozygotes, N=33 P-value 
LysoGb3 in sera (ng/ml), mean ± SD, (range) 51 ± 39, (5.3-148) 9.3 ± 5.6, (0.37-27) <0.001 
LysoGb3 in DBS (ng/ml), mean ± SD, (range) 31 ± 23, (3.1-89) 6.7 ± 3.3, (1.1-17) <0.001 
Hematocrit (L/L), mean ± SD 0.43 ± 0.04 0.41 ± 0.02 0.03 
Phenotype:     
Classic, n (%)  18 (78.3) 30 (90.9)  
Later-Onset, n (%) 5 (21.7) 3 (9.1)  
Mutation Type:    
Missense, n (%) 14 (60.9) 15 (45.4)  
Deletions, n (%) 5 (21.7) 5 (15.2)  
Duplications, n (%) 1 (4.3) 5 (15.2)  
Nonsense, n (%) 1 (4.3) 4 (12.1)  
Consensus Splice Site, n (%) 2 (8.8) 4 (12.1)  
Age in Years:    
Classic, mean ± SD, (range) 44 ± 12, (27-69) 47 ± 15, (20-70) 0.41 
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Later-Onset, mean ± SD, (range) 52 ± 13, (39-67) 51 ± 21, (35-75) 0.54 
On enzyme replacement:    
Classic, n (%) 15 (65.2) 20 (60.6)  
Later-Onset, n (%) 4 (17.4) 1 (3.0)  
 218 
* males not on ERT: 3 newly diagnosed, 1 due to compliance reasons.219 
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A linear regression model using serum Lyso-Gb3 levels as the dependent variable 220 
and DBS levels as the independent variable was described by the function y=-221 
1.83+1.68*x which had a very high coefficient of determination: R2= 0.976 (Figure 1).  222 
 223 
  224 
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 225 
 226 
 227 
Figure 1. Linear regression analysis for serum Lyso-Gb3 as the dependent variable 228 
and DBS Lyso-Gb3 as the independent variable.  229 
 230 
 231 
 232 
The bivariate correlation of the Lyso-Gb3 concentrations in DBS and sera from all FD 233 
patients regardless of phenotype were high: R=0.99 (p<0.001). The bivariate 234 
correlation of the Lyso-Gb3 concentrations in DBS and sera from healthy controls 235 
was low: R=0.65 (p=0.11).  236 
 237 
 238 
 239 
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4. Discussion 240 
These studies showed that the Lyso-Gb3 concentrations in DBS and sera were 241 
highly correlated. The Lyso-Gb3 level in sera can be estimated from the DBS 242 
concentration by multiplying the DBS value by 1.5 (see Figure 1). This provides a 243 
reasonable estimate of the serum Lyso-Gb3 level and is useful for monitoring therapy 244 
using the convenient DBS samples, which the patient can collect by a simple 245 
fingerpick. The DBS allow for home monitoring without a physician or hospital visit. 246 
Moreover, the DBS can be easily and inexpensively mailed to the test center for 247 
assay, so that routine monitoring is convenient.    248 
 249 
Importantly, when the DBS reproducibility was assessed in multiple samples of the 250 
same blood, the resulting values were highly reproducible. Similarly, when samples 251 
were stored for one month, the DBS values again were stable. Of note, there was a 252 
poor correlation of Lyso-Gb3 in DBS and sera in healthy controls due to the very low 253 
Lyso-Gb3 levels, which are at the limits of the assays sensitivity.  254 
Lyso-Gb3 has been has been shown to be increased in newborns [2, 31]. 255 
Previous studies have used DBS to measure Lyso-Gb3 levels [20, 21]. Chien et 256 
al [21] showed elevated Lyso-Gb3 levels in male adults, adolescents and most, 257 
but not all, male newborns with the Type 2 Later-Onset Taiwanese mutation, 258 
IVS4+919G>A . In heterozygotes, the Lyso-Gb3 concentrations in DBS were 259 
less diagnostic. Johnson et al [20] questioned the utility of DBS Lyso-Gb3 260 
levels in FD newborns because the levels were below their limit of quantitation 261 
in most newborn infants with FD. As shown in our studies, the Lyso-Gb3 262 
concentrations measured in DBS were about 50% lower than those measured 263 
in sera. Thus, a more sensitive DBS assay could be suitable for newborn 264 
screening to more reliably identify affected newborns with FD. However, in 265 
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adult at-risk populations, analysis of DBS Lyso-Gb3 with the current assay can 266 
be reliably used for screening of Classic males and heterozygotes as well as 267 
Later-Onset males. Therapeutic monitoring of the biochemical response to ERT 268 
is another application for Lyso-Gb3 determinations in DBS [17].” 269 
A limitation of this study is the fact that affected males and heterozygotes with the 270 
Later-Onset phenotype have only slightly elevated or normal Lyso-Gb3 levels, also 271 
shown previously by Smid et al [18]. Thus, Type 2 heterozygotes who have active 272 
disease and elevated Lyso-Gb3 levels should be considered for treatment [18, 19].  273 
 274 
Additional studies are needed to characterize the levels in more affected males and 275 
heterozygotes with the Later-Onset phenotype, as well as the development of more 276 
sensitive assays for Lyso-Gb3.  277 
 278 
 279 
5. Conclusion 280 
In summary, DBS samples provide a convenient and reliable means to estimate the 281 
Lyso-Gb3 correlations in serum or plasma and also permit the initial assignment of 282 
phenotype. Moreover, serial measurements of DBS Lyso-Gb3 allow for monitoring 283 
the effectiveness of various treatments.  284 
 285 
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